MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2024.10.002

Медицинская библиотека · American heart journal · 2024

Prospective study on the impact of different antithrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves-The NOTION-4 trial.

Thuraiaiyah Jani, Jørgensen Troels Højsgaard, Jensen Jesper Møller, Fuchs Andreas, Willemen Yannick, Terkelsen Christian Juhl, Kofoed Klaus Fuglsang, Søndergaard Lars, Nørgaard Bjarne Linde, De Backer Ole

Протокол клинического исследованияСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Transcatheter aortic valve replacement (TAVR) has become the standard-of-care treatment for a majority of patients with severe, symptomatic aortic stenosis. The postprocedural antithrombotic therapeutic management is still a topic of debate and could affect the incidence of HALT, a phenomenon which can be assessed by 4-dimensional computed tomography (4DCT).

TRIAL

DESIGN

The NOTION-4 trial is a randomized controlled trial comprising TAVR patients with no indication for oral anticoagulant (OAC) therapy, comparing lifelong single antiplatelet therapy (standard arm) versus early 3-month direct oral anticoagulant (DOAC) therapy followed by single antiplateletet therapy (experimental arm). The incidence of HALT and clinical endpoints will be evaluated in both groups at 3 months, 1 year and 5 years after randomization. The primary endpoint is the number of patients with at least 1 bioprosthetic aortic valve leaflet with HALT as assessed by cardiac 4DCT imaging at 1 year. The trial is powered for superiority testing and started enrollment in 2021. In total, 324 patients will be included. The last patient is expected to be enrolled by the end of 2024 and the primary endpoint is to be presented in 2026.

CONCLUSION AND PERSPECTIVE: The NOTION-4 trial aims to study whether an early 3-month DOAC therapy after TAVR can result in a sustained lower incidence of HALT in transcatheter aortic valves. This trial holds the potential to give valuable insights into whether early OAC therapy should be integrated in future guidelines for post-TAVR antithrombotic therapeutic management.

TRIAL REGISTRATION: NOTION-4, ClinicalTrials.gov ID NCT06449469, https://clinicaltrials.gov/study/NCT06449469.

Для цитирования: Thuraiaiyah Jani, Jørgensen Troels Højsgaard, Jensen Jesper Møller, Fuchs Andreas, Willemen Yannick, Terkelsen Christian Juhl, Kofoed Klaus Fuglsang, Søndergaard Lars, Nørgaard Bjarne Linde, De Backer Ole. Prospective study on the impact of different antithrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves-The NOTION-4 trial.. American heart journal. 2024. DOI: 10.1016/j.ahj.2024.10.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.